ThermoGenesis Announces MXP Involvement in New Regenerative Medicine I...(which has pioneered the study of using b...),Health

Date:1/29/2009

which has pioneered the study of using bone marrow stem cells as therapy. Patients with CLI are often faced with the prospect of amputation and suffer high rates of morbidity and mortality. We are optimistic that our MXP technology will ultimately enable clinicians to achieve more successful outcomes for these patients," said Matthew Plavan, Chief Executive Officer of ThermoGenesis.

The MXP System is derived from ThermoGenesis' AXP(TM) AutoXpress technology platform, which is routinely used in cord blood banking processing by both private and public cord blood banks throughout the world. The MXP features a microprocessor controlled device and a dedicated single-use disposable set for isolating stem cells present in bone marrow aspirates. The offering represents first to market technology allowing clinicians to automate the volume reduction steps and cryopreservation of processed bone marrow aspirates. The output of the MXP is compatible for stem cell cryopreservation using the ThermoGenesis BioArchive(R) System.

A second initiative involves the use of the MXP to perform clinical research on bone marrow stem cell separation in point-of-care orthopedic procedures. In September 2008, ThermoGenesis announced the signing of a distribution agreement with Austin, Texas-based Celling Technologies that covers distribution rights for the field of use in orthopedics intraoperative or point-of-care applications.

"This partnership with Celling Technologies, a true innovator in the orthopedics industry, portends a significant opportunity for ThermoGenesis. We are in the process of completing our training and market introduction programs with them and look forward to a mutually beneficial relationship," Plavan noted.

"With the recent change in administrations in Washington, it is likely that there will be increased funding and support for stem cell research. We are hopeful that a more favorable climate can lead
'/>"/>

SOURCE ThermoGenesis Corp. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4
Related medicine technology :

1. British Midlands University Announces Use of Gene Technology to Fight Lethal Hospital Acquired Infection
2. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
3. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
4. Impact Medical Solutions Announces Appointment of New Director and Corporate Update
5. Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
6. ISTA Pharmaceuticals Announces Positive Results for Phase IIb Study of Ecabet Sodium
7. Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer
8. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
9. Kyowa Hakko Kirin Announces Development Policy for Anti-Parkinsons Disease Drug KW-6002 (Istradefylline)
10. Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
11. Beactica Announces Fragment-Based Drug Discovery Research Collaboration With GE Healthcare and Uppsala University